HEDIS®
Adult and Prenatal Immunization Measures

Lindsey Roth, Senior Research Associate
Kat Sobel, Senior Health Care Analyst

February 27, 2019
OVERVIEW OF HEDIS
HEDIS DATA REPORTING METHODS
ADULT IMMUNIZATION STATUS MEASURE
PRENATAL IMMUNIZATION STATUS MEASURE
MEASURE IMPLEMENTATION
Q&A
About NCQA
It all starts with HEDIS®

Health care’s most-used tool for improving performance

Allows for comparison of health plans across important dimensions of care and service
Desirable Attributes for Measures

To be meaningful, measures must balance several criteria

- **Relevant**
  - Meaningful to stakeholders
  - Important to enhanced health
  - Financial importance
  - Potential for improvement
  - Substantial variation

- **Scientifically Sound**
  - Evidence-based
  - Valid
  - Reliable

- **Feasible**
  - Precisely specified
  - Data availability
  - Reasonable collection effort
  - Can be audited
HEDIS Consensus Measure Development Process

- Selection
- Development
- Public Comment
- First Year
- Public Reporting
- Evaluation
- Ongoing Use
- Retirement
HEDIS Data Reporting Methods
HEDIS Data Sources and Collection Methods

Harnessing an evolving data landscape

Administrative Method: Transaction Data
Enrollment, Claims, Encounters

Hybrid Method: Administrative + Sample
Medical Record

Survey Method
CAHPS®, Medicare Health Outcomes Survey

Electronic Clinical Data Systems Method
EHRs, Registries, Case Management, Claims

Supplemental Data
Laboratory Results, Registries, others
NCQA’s Vision for Quality Measurement

Better data, better measures

- New data sources, improved content and flow
- Measures move beyond concepts limited by claims
- Programs use better measures
- Better accountability at all levels
- Measure harmonization across programs
- Standardized electronic data
- Meaningful, patient-centric measures
- Standardized, machine readable logic
### HEDIS Immunization Measures

<table>
<thead>
<tr>
<th>Measure Title</th>
<th>Data Source</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Childhood Immunization Services</strong></td>
<td>Hybrid</td>
<td>Vaccinations for children by age 2</td>
</tr>
<tr>
<td><strong>Immunizations for Adolescents</strong></td>
<td>Hybrid</td>
<td>Vaccinations for adolescents by age 13</td>
</tr>
<tr>
<td><strong>Flu Vaccinations for Adults Ages 18–64</strong></td>
<td>CAHPS</td>
<td>Flu vaccines for Medicaid members, age 18 to 64</td>
</tr>
<tr>
<td><strong>Flu Vaccinations for Adults Ages 65 and Older</strong></td>
<td>CAHPS</td>
<td>Flu vaccines for Medicare members, age 65 and older</td>
</tr>
<tr>
<td><strong>Pneumococcal Vaccination Status for Older Adults</strong></td>
<td>CAHPS</td>
<td>Pneumococcal vaccines for Medicare members, age 65 and older</td>
</tr>
<tr>
<td><strong>New in HEDIS 2019</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adult Immunization Status</strong></td>
<td>ECDS</td>
<td>Vaccinations for adults, age 19 and older</td>
</tr>
<tr>
<td><strong>Prenatal Immunization Status</strong></td>
<td>ECDS</td>
<td>Vaccinations for pregnant women</td>
</tr>
</tbody>
</table>
New Measures for Immunizations

**Guidelines** recommend the following vaccines

*Adults* - influenza; Td/Tdap; herpes zoster; pneumococcal

*Pregnant Women* - influenza and Tdap

**Gaps in care** have been found for both adults and pregnant women

**Opportunity for measures** to assess health plan performance on administration of these vaccines
Adult Immunization Status Measure
Adult Immunization Status

Measure Description

Percentage of members 19 years of age and older who are up-to-date on recommended routine vaccines:

• Influenza
• Td or Tdap
• Herpes zoster
• Pneumococcal

Commercial, Medicaid, Medicare
## Adult Immunization Status

*Percentage of adults who are up-to-date on routine vaccines*

<table>
<thead>
<tr>
<th>Measure Rate</th>
<th>Vaccines</th>
<th>Eligible Population Age Ranges</th>
<th>Medicare</th>
<th>Commercial / Medicaid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza Rate</td>
<td>Influenza vaccine received between July 1 of year prior to June 30 of measurement period.</td>
<td>66 &amp; older</td>
<td>19-65</td>
<td></td>
</tr>
<tr>
<td>Td/Tdap Rate</td>
<td>Td or Tdap vaccine within the past 10 years.</td>
<td>66 &amp; older</td>
<td>19-65</td>
<td></td>
</tr>
<tr>
<td>Zoster Rate</td>
<td>1 dose of live herpes zoster vaccine or 2 doses of recombinant herpes zoster vaccine on or after 50th birthday.</td>
<td>66 &amp; older</td>
<td>50-65</td>
<td></td>
</tr>
<tr>
<td>Pneumococcal Rate</td>
<td>Polysaccharide AND conjugate vaccine ≥ 12 months apart on or after age 60</td>
<td>66 &amp; older</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Composite Rate</td>
<td>Percent of vaccines received out of all recommended vaccines based on age.</td>
<td>66 &amp; older</td>
<td>19-65</td>
<td></td>
</tr>
</tbody>
</table>

*Excludes adults from all rates with history of immunocompromising conditions or chemotherapy, bone marrow transplant or in hospice during the measurement year*
Adult Immunization Status - Composite Scoring

<table>
<thead>
<tr>
<th>Vaccines</th>
<th>Member A</th>
<th>Member B</th>
<th>Member C</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Age 70</td>
<td>Age 68</td>
<td>Age 66</td>
</tr>
<tr>
<td>Influenza</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Td or Tdap</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zoster</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

12 immunizations needed = 58%
# Adult Immunization Status - Composite Scoring

<table>
<thead>
<tr>
<th>Vaccines</th>
<th>Member A Age 70</th>
<th>Member B Age 68</th>
<th>Member C Age 66</th>
<th>Composite Rate:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza</td>
<td></td>
<td>✓</td>
<td></td>
<td>7 immunizations provided</td>
</tr>
<tr>
<td>Td or Tdap</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>12 immunizations needed</td>
</tr>
<tr>
<td>Zoster</td>
<td></td>
<td></td>
<td>✓</td>
<td>= 58%</td>
</tr>
<tr>
<td>Pneumococcal</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
</tbody>
</table>
## Adult Immunization Status - Composite Scoring

<table>
<thead>
<tr>
<th>Vaccines</th>
<th>COMMERCIAL/MEDICAID PLANS</th>
<th>Composite Rate:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Member A Age 64</td>
<td>Member B Age 50</td>
</tr>
<tr>
<td>Influenza</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Td or Tdap</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zoster</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>
# Adult Immunization Status - Composite Scoring

<table>
<thead>
<tr>
<th>Vaccines</th>
<th>Member A Age 64</th>
<th>Member B Age 50</th>
<th>Member C Age 19</th>
<th>Composite Rate:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>4 immunizations provided</td>
</tr>
<tr>
<td>Td or Tdap</td>
<td>✓</td>
<td></td>
<td></td>
<td>8 immunizations needed</td>
</tr>
<tr>
<td>Zoster</td>
<td></td>
<td>✓</td>
<td>NA</td>
<td>= 50%</td>
</tr>
<tr>
<td>Pneumococcal</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>

**Rate:** 50%
Prenatal Immunization Status
Measure
Prenatal Immunization Status

Measure Description

Percentage of deliveries during the measurement period in which women received the following vaccinations:
- Influenza vaccine
- Tdap vaccine

Commercial, Medicaid
## Prenatal Immunization Status

*Percentage of deliveries in which women received influenza and Tdap vaccinations*

<table>
<thead>
<tr>
<th>Measure Rate</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza</td>
<td>Influenza vaccine between July 1 of the year prior to the measurement period and the delivery date</td>
</tr>
<tr>
<td>Tdap Rate</td>
<td>At least one Tdap vaccine during the pregnancy</td>
</tr>
<tr>
<td>Composite Rate</td>
<td>Deliveries where patients received both vaccines</td>
</tr>
</tbody>
</table>

*Excludes deliveries with a gestational age of less than 37 weeks and patients who are in hospice or using hospice services during the measurement period.*
## Prenatal Immunization Status - Composite Scoring

<table>
<thead>
<tr>
<th>Vaccines</th>
<th>Delivery 1</th>
<th>Delivery 2</th>
<th>Delivery 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tdap</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**COMMERCIAl/MEDICAID PLANS**

**Composite Rate:**

3 deliveries total = 33%
## Prenatal Immunization Status - Composite Scoring

<table>
<thead>
<tr>
<th></th>
<th>Delivery 1</th>
<th>Delivery 2</th>
<th>Delivery 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>Tdap</td>
<td>✓</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**COMMERCEIAL/MEDICAID PLANS**

**Composite Rate:**

1 delivery with both vaccines = 33%
Measure Implementation
HEDIS First-Year Analysis Process Overview

All new HEDIS measures are collected but not publicly reported for at least one reporting cycle

When assessing for public reporting NCQA considers:

- Feasibility (plans have the ability to report)
- Opportunity for improvement (performance gap)

Committee on Performance Measurement votes to approve measures for public reporting and use in programs
Timeline for New HEDIS Immunization Measures

Next steps

- June 2019: HEDIS 2019 data submission
- July-August 2019: First-year data analysis
- September 2019: Review with Committee on Performance Measurement
- Future: Approved for public reporting & use in NCQA programs